RELEASE DATE:  December 17, 2003
NOTICE:  NOT-DA-04-020 


National Institute on Drug Abuse (NIDA)

The National Institute on Drug Abuse (NIDA) intends to solicit 
proposals from qualified organizations having in-house capability to 
carry out the work for the development of analytical methods, carrying 
out quality control tests and performing stability studies for 
compounds and dosage forms to be used in the medications development 
program. The development of medications for the treatment of drug 
addiction is one of the major missions of the National Institute on 
Drug Abuse (NIDA). The Institute has been providing potential treatment 
drugs to investigators for use in preclinical toxicology evaluation,
pharmacological studies and clinical trials. The treatment drugs 
include both bulk drug substances (e.g., GBR-12909, tropane analogs, 
RPR 102681, etc.) and dosage forms (e.g., buprenorphine tablets, GBR-
12909 capsules, RPR 102681 capsules, etc.). These drugs are acquired by 
the Government from private industry, Government contractors/grantees 
or independent investigators. In order to assure the identity, 
strength, quality and purity of these materials, the Government has 
been performing quality control tests before distributing them to the 
research community. NIDA anticipates award of a three year 
incrementally funded completion type contract with options for two 
additional years and additional quantities. In order to handle 
substances under the Controlled Substances Act of 1970, it is mandatory 
that offerors possess a DEA Research Registration for Schedules II to V 
and demonstrate the capability to obtain a DEA registration for 
Schedule I controlled substances. If the offeror does not possess a DEA 
registration for controlled substances Schedules II through V, the 
proposal must indicate that application for such registration is in 
progress and assurance must be provided that such application will be
 successful (documentation to be provided of adequately secure storage 
facilities, etc.). RFP No. N01DA-4-8844 will be available 
electronically on or about January 12, 2004. You can access The RFP 
through the FedBizOpps (URL: or through the 
NIDA website at the following address: (URL: Please note that the RFP for 
this acquisition will be streamlined to include only the Work    
Statement, Deliverables, Reporting Requirements, Special Requirements, 
Mandatory Qualifications, Technical Evaluation Criteria, and other 
necessary Proposal Preparation Instructions. However, all information 
required for the submission of an offer will be contained in or 
accessible through the streamlined electronic RFP package. Responses to 
the RFP will be due on or about February 26, 2004. This advertisement 
does not commit the Government to award a contract. See Note 26. 

Original Point of Contact

Dawn Rabunsky, Contract Specialist, NIDA/NIH, Phone 301 443-6677, Fax 
301 443-7595, Email - Nancy Hurd, Contracting Officer,
Phone (301) 443-6677, Fax (301) 443-7595, Email

Return to Volume Index

Return to NIH Guide Main Index

Office of Extramural Research (OER) - Home Page Office of Extramural
Research (OER)
  National Institutes of Health (NIH) - Home Page National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892
  Department of Health and Human Services (HHS) - Home Page Department of Health
and Human Services (HHS) - Government Made Easy

Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.